Cancer Discov. 2017 Aug;7(8):OF10. doi: 10.1158/2159-8290.CD-NB2017-085. Epub 2017 Jun 5.
In the phase III OlympiAD study, tumors shrank in about 60% of women with mutation-associated metastatic breast cancer who received the PARP inhibitor olaparib compared with 29% who received chemotherapy; the median time to disease progression was 7 months compared with 4.2 months, respectively. These findings are the first to demonstrate that a PARP inhibitor can improve progression-free survival in metastatic, hereditary breast cancer.
在 III 期 OlympiAD 研究中，与接受化疗的患者相比，携带突变的转移性乳腺癌女性中，接受 PARP 抑制剂奥拉帕利治疗的患者肿瘤缩小约 60%；疾病进展的中位时间分别为 7 个月和 4.2 个月。这些发现首次证明 PARP 抑制剂可以改善转移性遗传性乳腺癌的无进展生存期。
